pt3 myr akt addgene  (Addgene inc)

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells

doi: 10.1155/2022/8110796

Figure Lengend Snippet: PF-04691502 inhibits the PI3K/Akt/mTOR pathway in bladder cancer cells. (a) T-24 and 5637 cells were treated with the indicated doses of PF-04691502 for 24 (h) and the levels of specific proteins were measured using western blot. (b) T-24 and 5637 cells were transfected with an empty vector (EV) or a vector expressing myr-Akt (OV Akt) for 12 h; then, the cells were treated with or without PF-04691502 for another 24 h and the specific proteins were measured using western blots. (c) T-24 and 5637 cells were treated as indicated above, and cellular apoptosis was measured. (d) Cellular viabilities of the cells were measured. Data are representative of at least three independent experiments ( ∗ P < 0.05; ∗∗ P < 0.01).

Article Snippet: The myr-Akt vector was purchased from Addgene (USA). siRNA against PTEN (si-PTEN) and negative scramble control (si-NC) were purchased from RioBio Ltd. (China).

Techniques: Western Blot, Transfection, Plasmid Preparation, Expressing